University of California San Francisco

Laura J. Esserman - 144x
Laura
Esserman
MD, MBA

Professor of Surgery and Radiology
Chief, Section of Breast Care Surgery
Division of Surgical Oncology
Alfred A. de Lorimier Endowed Chair in General Surgery
Director, UCSF Breast Care Center

Address

550 16th Street, #6313
San Francisco, CA 94158
United States

Email: [email protected]
Phone: 415-885-7691

Biography

Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care. She is a professor of Surgery & Radiology at UCSF and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.

She is the Principal Investigator of the I-SPY TRIAL program, a multi-site neoadjuvant clinical trial that has evolved into a model for translational research and innovation in clinical trial design.

Dr. Esserman launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a project designed to follow 400,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care.

Dr. Esserman is nationally and internationally known as a leader in the field of breast cancer and has published over 200 articles in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally. Overall, Dr. Esserman's research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.

She was a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation, which studied how the federal government can best support science-based innovation in the process of drug development and regulatory evaluation. In addition, she was a contributing member of a “taskforce” for President Obama’s Council of Advisors on Science and Technology.

Dr. Esserman received her Bachelor's degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center. After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993. She then joined the faculty at the University of California, San Francisco.

Education

Education

1974-77, Harvard University, A.B.
1978-83, Stanford University, M.D.

Residencies

1983-85, Stanford University School of Medicine, Resident, General Surgery
1988-90, Stanford University School of Medicine, Resident, General Surgery
1990-91, Stanford University School of Medicine, Chief Resident, General Surgery

Fellowships

1985-88, Stanford University School of Medicine, Postdoctoral Fe, Oncology, Medical

Postdoctoral Training

1991-93, Stanford University, M.B.A.

Board Certifications

American Board of Surgery - General Surgery - 1992

Collaboration Interests

I am interested in:

  • policy change

Clinical Expertise

DCIS (Ductal Carcinoma in situ)
Inflammatory Breast Cancer
Invasive Breast Cancer
LCIS (Lobular Carcinoma in situ)
Lumpectomy/Partial Mastectomy
Lymphadenectomy
Mastectomy
Recurrent Breast Cancer
Sentinel Lymph Node Biopsy
Wire Localization Surgery

Program Affiliations

  • UCSF Center of Excellence for Breast Cancer Care
  • UCSF Breast Care Center
  • UCSF Helen Diller Comprehensive Cancer Center

 

Translational Co-Lead: Dr. Laura Esserman, is internationally recognized for her leadership of the ground-breaking I-SPY2 clinical trial and as an advocate for de-escalation of treatment for DCIS, and the initiation of the virtual preference pragmatic personalized screening trial (WISDOM) seeking to personalize the approach to screening. Her work in breast cancer spans the spectrum from public policy issues to basic science and the impact of both on the delivery of clinical care. Dr. Esserman has mentored 36 post-doctoral or clinical fellows during her career. She developed and runs a post-baccalaureate program that has trained 123 students over the past 15 years, most of whom have gone on to careers in medicine.

Dr. Esserman’s broad research interests provide exceptional opportunities for multidisciplinary training across the three themes, through clinical trials and biomarker studies on screening, prevention and treatment of breast cancer, many of which focus on improving healthcare value. Another fundamental and scalable effort is the implementation of systems to integrate care and research.

Grants and Funding

  • Surgical Oncology Training Grant | NIH | 2020-07-15 - 2025-06-30 | Role: Principal Investigator
  • Extending the Diversity, Reach, and Generalizability of the WISDOM Study | NIH | 2020-03-01 - 2025-02-28 | Role: Principal Investigator
  • I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes | NIH | 2017-09-08 - 2022-08-31 | Role: Principal Investigator
  • Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers | NIH | 2015-09-16 - 2021-08-31 | Role: Principal Investigator
  • Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes | NIH | 2014-09-18 - 2020-08-31 | Role: Principal Investigator
  • Integrated Biomarkers to Characterize Breast Cancer Risk | NIH | 2004-09-20 - 2011-06-30 | Role: Principal Investigator

Research Interests

  • BRCA1 Protein
  • BRCA2 Protein
  • Breast Diseases
  • Breast Neoplasms
  • Male
  • Mastectomy
  • Segmental
  • Ultrasonography
  • Mammary
  • Cancer Vaccines
  • Genes
  • Tumor Suppressor
  • Oncogenes
  • Precancerous Conditions
  • Infiltrating Duct Carcinoma
  • Intraductal Carcinoma
  • Noninfiltrating Carcinoma Lobular

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 453
  1. A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
    Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M, Valdez J, Morgan T, Garber J, Esserman L| | PubMed
  2. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L| | PubMed
  3. Screening Mammography for 40-Year-Old Women-Whose Decision?
    Kerlikowske K, Esserman L, Tice JA| | PubMed
  4. Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
    McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ| | PubMed
  5. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
    Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer LJV', Esserman L, Rugo HS| | PubMed
  6. Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
    Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ| | PubMed
  7. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ| | PubMed
  8. Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.
    Fabian CJ, Mudaranthakam DP, Gajewski B, Young K, Winblad O, Khan SA, Garber JE, Esserman LJ, Yee LD, Nye L, Powers KR, Ranallo L, Kreutzjans AL, Pittman K, Altman C, Metheny T, Zelenchuk A, Komm BS, Kimler BF| | PubMed
  9. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ| | PubMed
  10. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ| | PubMed
  11. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A| | PubMed
  12. Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.
    Franklin JB, Marra C, Abebe KZ, Butte AJ, Cook DJ, Esserman L, Fleisher LA, Grossman CI, Kass NE, Krumholz HM, Rowan K, Abernethy AP, JAMA Summit on Clinical Trials Participants| | PubMed
  13. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  14. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA| | PubMed
  15. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group| | PubMed
  16. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  17. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L| | PubMed
  18. Reproductive rights in the United States: acquiescence is not a strategy.
    Esserman LJ, Yee D| | PubMed
  19. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME, Wulfkuhle J, Gallagher RI, Gomez H, Isaacs C, Bharti V, Wilson JT, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Hirst GL, Brown Swigart L, van 't Veer LJ, Esserman LJ, Petricoin EF, Pietenpol JA, Balko JM| | PubMed
  20. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
    Ríos-Hoyo A, Cobain E, Huppert LA, Beitsch PD, Buchholz TA, Esserman L, van 't Veer LJ, Rugo HS, Pusztai L| | PubMed
  21. RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    Omoleye OJ, Esserman LJ, Olopade OI| | PubMed
  22. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
    Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND| | PubMed
  23. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Yu S, Hirst G, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H| | PubMed
  24. 18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
    Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM| | PubMed
  25. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA| | PubMed
  26. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
    Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, Dewar R, Lane HC, Lallemand P, Liu KD, Esserman L, Matthay MA, Calfee CS, I-SPY COVID Consortium| | PubMed
  27. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
    Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ| | PubMed
  28. Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.
    O'Keefe T, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, McGuire J, Griffin A, Wallace A, Esserman L, Harismendy O, Hirst G| | PubMed
  29. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
    Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ| | PubMed
  30. Precision Oncology in Breast Cancer Surgery.
    Abbasi AB, Wu V, Lang JE, Esserman LJ| | PubMed
  31. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF| | PubMed
  32. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI| | PubMed
  33. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
    Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME| | PubMed
  34. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA| | PubMed
  35. Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
    Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Castaño JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, Melmed S| | PubMed
  36. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA| | PubMed
  37. Early Ascertainment of Breast Cancer Diagnoses Comparing Self-Reported Questionnaires and Electronic Health Record Data Warehouse: The WISDOM Study.
    Leggat-Barr K, Ryu R, Hogarth M, Stover-Fiscalini A, Veer LV', Park HL, Lewis T, Thompson C, Borowsky A, Hiatt RA, LaCroix A, Parker B, Madlensky L, Naeim A, Esserman L| | PubMed
  38. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA| | PubMed
  39. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA| | PubMed
  40. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network| | PubMed
  41. A Truly Pro-Life Position Requires Access to Reproductive Health Care.
    Hull SC, Chou JC, Yee LM, Yee D, Esserman L| | PubMed
  42. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA| | PubMed
  43. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group| | PubMed
  44. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M| | PubMed
  45. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.
    Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, Pu A, Shen L, Sieh W, Yoon HC, Lee C| | PubMed
  46. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    Mukhtar RA, Yau C, Esserman LJ| | PubMed
  47. Development and testing of a polygenic risk score for breast cancer aggressiveness.
    Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer LV, Esserman LJ, Ziv E| | PubMed
  48. Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.
    Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ| | PubMed
  49. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  50. Time to Surgery in Breast Cancer-Is Faster Always Better?
    Mukhtar RA, Esserman LJ| | PubMed
  51. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ| | PubMed
  52. Guiding principles for the responsible development of artificial intelligence tools for healthcare.
    Badal K, Lee CM, Esserman LJ| | PubMed
  53. Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
    Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D| | PubMed
  54. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
    Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N| | PubMed
  55. When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
    Esserman LJ, Ali H, McKenzie T| | PubMed
  56. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M| | PubMed
  57. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A| | PubMed
  58. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  59. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  60. Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A| | PubMed
  61. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA| | PubMed
  62. Informed consent process in the ISPY COVID trial is ethically acceptable.
    Files DC, Esserman L, Liu KD, Calfee CS| | PubMed
  63. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment.
    Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE| | PubMed
  64. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
    Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM| | PubMed
  65. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS| | PubMed
  66. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.
    Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, Scholten AN, Schröder CP, Elias SG, Kroep JR, Portielje JEA, Kleijn M, Liefers GJ| | PubMed
  67. Why It Is Time to Challenge Entrenched Beliefs About Breast Cancer Screening.
    Esserman LJ, Parker BA, LaCroix AZ| | PubMed
  68. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A| | PubMed
  69. Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.
    Chien AJ, Kyalwazi B, Esserman LJ| | PubMed
  70. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.
    Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD, ISPY COVID Adaptive Platform Trial Network, undefined| | PubMed
  71. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ| | PubMed
  72. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium| | PubMed
  73. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
    Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM| | PubMed
  74. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    Mukhtar R, Symmans WF, Esserman LJ| | PubMed
  75. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
    Johansson A, Yu NY, Iftimi A, Tobin NP, van 't Veer L, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, Esserman LJ, Yau C, Lindström LS| | PubMed
  76. Survivorship after neoadjuvant chemotherapy - Authors' reply.
    Yau C, Osdoit M, Esserman LJ, Symmans WF| | PubMed
  77. Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
    Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M| | PubMed
  78. Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    Lopes Cardozo JMN, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, van 't Veer LJ| | PubMed
  79. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O| | PubMed
  80. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA| | PubMed
  81. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF| | PubMed
  82. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Dreher N, Matthys M, Hadeler E, Shieh Y, Acerbi I, McAuley FM, Melisko M, Eklund M, Tice JA, Esserman LJ, Veer LJV| | PubMed
  83. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
    Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM| | PubMed
  84. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A| | PubMed
  85. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ| | PubMed
  86. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA| | PubMed
  87. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ| | PubMed
  88. Pre-Appointment Nurse Navigation: Patient-Centered Findings From a Survey of Patients With Breast Cancer.
    Wang T, Huilgol YS, Black J, D'Andrea C, James J, Northrop A, Belkora J, Esserman LJ| | PubMed
  89. Health screening needs independent regular re-evaluation.
    Ropers FG, Barratt A, Wilt TJ, Nicholls SG, Taylor-Phillips S, Kramer BS, Esserman LJ, Norris SL, Gibson LM, Harris RP, Carter SM, Jacklyn G, Jørgensen KJ| | PubMed
  90. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    Khoury AL, Keane H, Varghese F, Hosseini A, Mukhtar R, Eder SE, Weinstein PR, Esserman LJ| | PubMed
  91. The WISDOM study: a new approach to screening can and should be tested.
    Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M| | PubMed
  92. The use of neoadjuvant therapy to further personalize breast cancer treatment.
    Esserman LJ| | PubMed
  93. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM| | PubMed
  94. Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
    Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ| | PubMed
  95. Authors' Reply: To the Letter to the Editor by Groheux et al.
    Heath CL, Esserman LJ, Flavell RR, Melisko ME| | PubMed
  96. Advancing precision medicine for acute respiratory distress syndrome.
    Beitler JR, Thompson BT, Baron RM, Bastarache JA, Denlinger LC, Esserman L, Gong MN, LaVange LM, Lewis RJ, Marshall JC, Martin TR, McAuley DF, Meyer NJ, Moss M, Reineck LA, Rubin E, Schmidt EP, Standiford TJ, Ware LB, Wong HR, Aggarwal NR, Calfee CS| | PubMed
  97. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ| | PubMed
  98. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
    Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  99. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA| | PubMed
  100. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A| | PubMed
  101. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS| | PubMed
  102. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ| | PubMed
  103. Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
    Matthys MB, Dempsey AM, Melisko ME, Dreher N, Che ML, Van't Veer LJ, Esserman LJ, Basu A| | PubMed
  104. Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.
    Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y| | PubMed
  105. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
    Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L| | PubMed
  106. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA| | PubMed
  107. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF| | PubMed
  108. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
    Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ| | PubMed
  109. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    Scheepens JCC, Veer LV', Esserman L, Belkora J, Mukhtar RA| | PubMed
  110. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    Hansen KS, Ghersin H, Piper M, Tavakol M, Lee B, Esserman LJ, Roberts JP, Freise C, Ascher NL, Mukhtar RA| | PubMed
  111. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
    Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, Hogewoning SJ, Lips EH, Vrancken Peeters MT, Kok NF, Wiersma T, Esserman L, van 't Veer LJ, Linn SC, Siesling S, Sonke GS| | PubMed
  112. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M| | PubMed
  113. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
    Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ| | PubMed
  114. Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.
    Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK| | PubMed
  115. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
    Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF| | PubMed
  116. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
    Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM| | PubMed
  117. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ| | PubMed
  118. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O| | PubMed
  119. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
    Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME| | PubMed
  120. Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M| | PubMed
  121. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
    Basu A, Philip EJ, Dewitt B, Hanmer J, Chattopadhyay A, Yau C, Melisko ME, Esserman LJ| | PubMed
  122. The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment.
    Hewitt K, Son J, Glencer A, Borowsky AD, Cooperberg MR, Esserman LJ| | PubMed
  123. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA| | PubMed
  124. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L| | PubMed
  125. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA| | PubMed
  126. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective.
    Sharib J, Esserman L, Koay EJ, Maitra A, Shen Y, Kirkwood KS, Ozanne EM| | PubMed
  127. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
    Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators| | PubMed
  128. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA| | PubMed
  129. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA| | PubMed
  130. Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M| | PubMed
  131. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM| | PubMed
  132. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
    Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM| | PubMed
  133. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
    Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM| | PubMed
  134. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM| | PubMed
  135. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ| | PubMed
  136. Personalization of Treatment is the Way Forward in Care and Trials.
    Esserman LJ| | PubMed
  137. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H| | PubMed
  138. Response to Carter et al.
    Eklund M, Broglio K, Yau C, Connor JT, Fiscalini AS, Esserman LJ| | PubMed
  139. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
    Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N| | PubMed
  140. We need more evidence to answer questions about screening.
    Esserman L| | PubMed
  141. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS| | PubMed
  142. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA| | PubMed
  143. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
    Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS| | PubMed
  144. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
    Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ| | PubMed
  145. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW| | PubMed
  146. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
    Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME| | PubMed
  147. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
    Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium, Esserman LJ, Hylton NM| | PubMed
  148. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM| | PubMed
  149. A response to "Personalised medicine and population health: breast and ovarian cancer".
    Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E| | PubMed
  150. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium| | PubMed
  151. Should we rename low risk cancers?
    Esserman LJ, Varma M| | PubMed
  152. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    Ozanne EM, Howe R, Mallinson D, Esserman L, Van't Veer LJ, Kaplan CP| | PubMed
  153. The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
    Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscalini A, Esserman LJ| | PubMed
  154. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators| | PubMed
  155. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E| | PubMed
  156. Precision risk-based screening might maximize benefit and minimize harm.
    Esserman LJ, LaCroix AZ| | PubMed
  157. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
    Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators| | PubMed
  158. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
    Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW| | PubMed
  159. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
    Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM, ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators| | PubMed
  160. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators| | PubMed
  161. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
    Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF| | PubMed
  162. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
    Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y| | PubMed
  163. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L| | PubMed
  164. The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.
    Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS| | PubMed
  165. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, STO Trialists Group| | PubMed
  166. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K| | PubMed
  167. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers.
    Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR, Beswick A, Greenwood R, Ingram JC, Saunders C, Vaidya JS, Esserman L, Jatoi I, Brunt AM| | PubMed
  168. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network| | PubMed
  169. Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy.
    Chiu C, Aleshi P, Esserman LJ, Inglis-Arkell C, Yap E, Whitlock EL, Harbell MW| | PubMed
  170. Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization.
    Price ER, Khoury AL, Esserman LJ, Joe BN, Alvarado MD| | PubMed
  171. Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction.
    Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B| | PubMed
  172. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
    Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC| | PubMed
  173. Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
    Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM| | PubMed
  174. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    DeMichele A, Yee D, Esserman L| | PubMed
  175. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS| | PubMed
  176. The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H| | PubMed
  177. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME| | PubMed
  178. The WISDOM Study: breaking the deadlock in the breast cancer screening debate.
    Esserman LJ, WISDOM Study and Athena Investigators| | PubMed
  179. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L| | PubMed
  180. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L| | PubMed
  181. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS| | PubMed
  182. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP| | PubMed
  183. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A| | PubMed
  184. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY| | PubMed
  185. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N, Yau C, Li J, Esserman LJ, Rugo HS| | PubMed
  186. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP| | PubMed
  187. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS| | PubMed
  188. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
    Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T| | PubMed
  189. Precision surgery and avoiding over-treatment.
    Hosseini A, Khoury AL, Esserman LJ| | PubMed
  190. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA, Athena Breast Health Network Investigators| | PubMed
  191. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K| | PubMed
  192. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM| | PubMed
  193. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
    Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM, ACRIN Trial team ISPY-1 Investigators| | PubMed
  194. Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction?
    Wang F, Chin R, Piper M, Esserman L, Sbitany H| | PubMed
  195. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
    Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network| | PubMed
  196. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C| | PubMed
  197. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L| | PubMed
  198. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Berry D, Esserman L| | PubMed
  199. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.
    Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ| | PubMed
  200. The I-SPY approach to drug development.
    Esserman L| | PubMed
  201. Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences.
    Esserman LJ, Thompson IM| | PubMed
  202. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ| | PubMed
  203. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators| | PubMed
  204. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators| | PubMed
  205. When Less Is Better, but Physicians Are Afraid Not to Intervene.
    Esserman L| | PubMed
  206. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
    Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS| | PubMed
  207. Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review.
    Piper ML, Esserman LJ, Sbitany H, Peled AW| | PubMed
  208. Population-based screening for cancer: hope and hype.
    Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ| | PubMed
  209. When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature.
    Borowsky A, Esserman L| | PubMed
  210. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
    Esserman L, Yau C| | PubMed
  211. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
    Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM| | PubMed
  212. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN| | PubMed
  213. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
    Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM, MIAMI (Multiple Ipsilateral breast conserving surgery versus mastectomy) Trial Management Group| | PubMed
  214. Detection of ductal carcinoma in situ and subsequent interval cancers.
    Shieh Y, Eklund M, Esserman L| | PubMed
  215. CLINICAL DECISIONS. Ductal Carcinoma In Situ.
    Merrill AL, Esserman L, Morrow M| | PubMed
  216. Less Is More: The Evolving Surgical Approach to Breast Cancer.
    Esserman L, Gallant E, Alvarado M| | PubMed
  217. Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
    DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ, I-SPY2 Investigators| | PubMed
  218. The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction.
    Wang F, Peled AW, Chin R, Fowble B, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H| | PubMed
  219. Tissue Expander Reconstruction After Total Skin-Sparing Mastectomy: Defining the Effects of Coverage Technique on Nipple/Areola Preservation.
    Sbitany H, Wang F, Peled AW, Alvarado M, Ewing CA, Esserman LJ, Foster RD| | PubMed
  220. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome.
    Johnson J, Esserman L, Ewing C, Alvarado M, Park C, Fowble B| | PubMed
  221. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators| | PubMed
  222. Rethinking the Standard for Ductal Carcinoma In Situ Treatment.
    Esserman L, Yau C| | PubMed
  223. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ| | PubMed
  224. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
    Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP| | PubMed
  225. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF, Residual Disease Characterization Working Group of the Breast International Group-North American Bre| | PubMed
  226. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ| | PubMed
  227. Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?
    Peled AW, Wang F, Foster RD, Alvarado M, Ewing CA, Sbitany H, Esserman LJ| | PubMed
  228. In Regard to Hepel and Wazer.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M| | PubMed
  229. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    Mukhtar RA, Wong JM, Esserman LJ| | PubMed
  230. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
    Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ| | PubMed
  231. Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management.
    Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman LJ| | PubMed
  232. Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program.
    Belkora J, Volz S, Loth M, Teng A, Zarin-Pass M, Moore D, Esserman L| | PubMed
  233. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
    Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration| | PubMed
  234. Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction.
    Piper M, Peled AW, Sbitany H, Foster RD, Esserman LJ, Price ER| | PubMed
  235. Approaches to microvascular breast reconstruction after total skin-sparing mastectomy: a comparison of techniques.
    Raghavan S, Peled AW, Hansen SL, Esserman LJ, Sbitany H| | PubMed
  236. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy.
    Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A| | PubMed
  237. Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M, TARGIT trialists' group| | PubMed
  238. The impact of breast mass on outcomes of total skin-sparing mastectomy and immediate tissue expander-based breast reconstruction.
    Wang F, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H| | PubMed
  239. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
    DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ| | PubMed
  240. Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization.
    Warner JL, Maddux SE, Hughes KS, Krauss JC, Yu PP, Shulman LN, Mayer DK, Hogarth M, Shafarman M, Stover Fiscalini A, Esserman L, Alschuler L, Koromia GA, Gonzaga Z, Ambinder EP| | PubMed
  241. Preoperative Breast Pain Predicts Persistent Breast Pain and Disability After Breast Cancer Surgery.
    Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, Hamolsky D, Mastick J, Paul SM, Cooper B, Kober K, Dodd M, Dunn L, Aouizerat B, Miaskowski C| | PubMed
  242. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
    Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS| | PubMed
  243. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer.
    Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME| | PubMed
  244. Expression profiling of circulating tumor cells in metastatic breast cancer.
    Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW| | PubMed
  245. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes.
    Sbitany H, Wang F, Peled AW, Lentz R, Alvarado M, Ewing CA, Esserman LJ, Fowble B, Foster RD| | PubMed
  246. Aggregate cost of mammography screening in the United States.
    Eklund M, O'Donoghue C, Esserman LJ| | PubMed
  247. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction.
    Degnim AC, Hoskin TL, Brahmbhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, Ballman K, Baddour LM, Esserman LJ| | PubMed
  248. Haste makes waste, but lack of urgency is opportunity lost.
    Esserman L, Hayes M, Alvarado M| | PubMed
  249. Impact of total skin-sparing mastectomy incision type on reconstructive complications following radiation therapy.
    Peled AW, Foster RD, Ligh C, Esserman LJ, Fowble B, Sbitany H| | PubMed
  250. Moving beyond the breast cancer screening debate.
    Esserman L, O'Kane ME| | PubMed
  251. Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes.
    Wang F, Peled AW, Garwood E, Fiscalini AS, Sbitany H, Foster RD, Alvarado M, Ewing C, Hwang ES, Esserman LJ| | PubMed
  252. Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile.
    Sbitany H, Wang F, Saeed L, Alvarado M, Ewing CA, Esserman LJ, Foster RD| | PubMed
  253. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.
    Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM| | PubMed
  254. Addressing overdiagnosis and overtreatment in cancer: a prescription for change.
    Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S| | PubMed
  255. Fifty years of age-based screening: time for a new risk-based screening approach.
    Kerlikowske K, O'Kane ME, Esserman LJ| | PubMed
  256. Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
    Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ| | PubMed
  257. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy.
    Peled AW, Sbitany H, Foster RD, Esserman LJ| | PubMed
  258. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction.
    Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, Sbitany H| | PubMed
  259. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?
    Esserman LJ, DeMichele A| | PubMed
  260. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).
    Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A, I-SPY1 Investigators| | PubMed
  261. Setting a research agenda for ductal carcinoma in situ that meets the current need for change.
    Esserman L, Alvarado M| | PubMed
  262. Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time?
    Esserman LJ, Alvarado MD, Howe RJ, Mohan AJ, Harrison B, Park C, O'Donoghue C, Ozanne EM| | PubMed
  263. Abstract 124: outcomes of total skin-sparing mastectomy and reconstruction in 924 breasts over 11 years.
    Wang F, Peled A, Foster R, Wang E, Ewing C, Alvarado M, Esserman L, Sbitany H| | PubMed
  264. Making better doctors: a survey of premedical interns working as health coaches.
    Zarin-Pass M, Belkora J, Volz S, Esserman L| | PubMed
  265. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG, Northwestern Cancer Genetics Group| | PubMed
  266. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines.
    O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ| | PubMed
  267. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.
    Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM| | PubMed
  268. Mammographic screening detects low-risk tumor biology breast cancers.
    Drukker CA, Schmidt MK, Rutgers EJ, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, Van't Veer LJ| | PubMed
  269. Development of a personalized decision aid for breast cancer risk reduction and management.
    Ozanne EM, Howe R, Omer Z, Esserman LJ| | PubMed
  270. Changing the terminology of cancer--reply.
    Esserman LJ, Thompson IM, Reid BJ| | PubMed
  271. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
    Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM| | PubMed
  272. Evolving paradigm for imaging, diagnosis, and management of DCIS.
    Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ| | PubMed
  273. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery.
    Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM| | PubMed
  274. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M, TARGIT trialists' group| | PubMed
  275. Screening: biology dictates the fate of young women with breast cancer.
    Eklund M, Esserman LJ| | PubMed
  276. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ| | PubMed
  277. Impact of ductal carcinoma in situ terminology on patient treatment preferences.
    Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM| | PubMed
  278. Overdiagnosis and overtreatment in cancer: an opportunity for improvement.
    Esserman LJ, Thompson IM, Reid B| | PubMed
  279. Total skin-sparing mastectomy in BRCA mutation carriers.
    Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ| | PubMed
  280. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care.
    Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman LJ, Athena Breast Health Network| | PubMed
  281. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
    Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM| | PubMed
  282. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ| | PubMed
  283. Feasibility of Performing Total Skin-Sparing Mastectomy in Patients With Prior Circumareolar Mastopexy or Reduction Mammoplasty Incisions.
    Vaughn CJ, Peled AW, Esserman LJ, Foster RD| | PubMed
  284. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.
    Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman LJ| | PubMed
  285. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.
    O'Donoghue C, Esserman L| | PubMed
  286. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications.
    Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ| | PubMed
  287. Developing safety criteria for introducing new agents into neoadjuvant trials.
    DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L| | PubMed
  288. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy.
    Peled AW, Esserman LJ| | PubMed
  289. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC| | PubMed
  290. Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions.
    Pass M, Volz S, Teng A, Esserman L, Belkora J| | PubMed
  291. Will early detection for breast cancer ever work?
    Esserman L, Ozanne E, van't Veer L| | PubMed
  292. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
    Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L| | PubMed
  293. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
    Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American Society of Clinical Oncology| | PubMed
  294. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.
    Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L, I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF| | PubMed
  295. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators| | PubMed
  296. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
    Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ| | PubMed
  297. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure.
    Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B| | PubMed
  298. Breast cancer screening: the questions answered.
    Autier P, Esserman LJ, Flowers CI, Houssami N| | PubMed
  299. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
    Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M| | PubMed
  300. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer.
    Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L| | PubMed
  301. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ| | PubMed
  302. Whole-genome analysis informs breast cancer response to aromatase inhibition.
    Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER| | PubMed
  303. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
    Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M, BIG-NABCG collaboration| | PubMed
  304. Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy.
    Chang EI, Peled AW, Foster RD, Lin C, Zeidler KR, Ewing CA, Alvarado M, Hwang ES, Esserman LJ| | PubMed
  305. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators| | PubMed
  306. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study.
    Peled AW, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, Hwang ES, Esserman LJ| | PubMed
  307. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N| | PubMed
  308. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ| | PubMed
  309. Breast cancer recurrence is dictated by high-risk biology, not choice of surgery.
    Esserman LJ| | PubMed
  310. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts.
    Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, Hwang ES, Esserman LJ| | PubMed
  311. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
    Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A| | PubMed
  312. Overdiagnosis and overtreatment of breast cancer.
    Alvarado M, Ozanne E, Esserman L| | PubMed
  313. Targeting Molecular Aberrations in Breast Cancer: Is It about Time?
    Esserman L, Benz C, Demichele A| | PubMed
  314. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators| | PubMed
  315. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J| | PubMed
  316. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
    Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR| | PubMed
  317. Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
    Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ| | PubMed
  318. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
    Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES| | PubMed
  319. Leukocyte composition of human breast cancer.
    Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM| | PubMed
  320. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators| | PubMed
  321. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ| | PubMed
  322. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC| | PubMed
  323. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
    Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF| | PubMed
  324. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA| | PubMed
  325. Characterizing the impact of 25 years of DCIS treatment.
    Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ| | PubMed
  326. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.
    Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES| | PubMed
  327. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ| | PubMed
  328. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC| | PubMed
  329. The Communication and Care Plan: a novel approach to patient-centered clinical information systems.
    Hogarth M, Hajopoulos K, Young M, Cowles N, Churin J, Hornthal B, Esserman L| | PubMed
  330. Long-term prognostic role of functional limitations among women with breast cancer.
    Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ| | PubMed
  331. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
    Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ| | PubMed
  332. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience.
    Liu LC, Lang JE, Lu Y, Roe D, Hwang SE, Ewing CA, Esserman LJ, Morita E, Treseler P, Leong SP| | PubMed
  333. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
    Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES| | PubMed
  334. Lessons learned from genetic testing.
    Esserman L, Kaklamani V| | PubMed
  335. Expanding the reach of decision and communication aids in a breast care center: a quality improvement study.
    Belkora JK, Teng A, Volz S, Loth MK, Esserman LJ| | PubMed
  336. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
    Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M| | PubMed
  337. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
    Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B| | PubMed
  338. Solving the overdiagnosis dilemma.
    Esserman L, Thompson I| | PubMed
  339. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ| | PubMed
  340. Application of screening principles to the reconstructed breast.
    Zakhireh J, Fowble B, Esserman LJ| | PubMed
  341. Rethinking screening for breast cancer and prostate cancer.
    Esserman L, Shieh Y, Thompson I| | PubMed
  342. Bacteriologic features of surgical site infections following breast surgery.
    Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES| | PubMed
  343. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
    Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES| | PubMed
  344. A comparison of RNA amplification techniques at sub-nanogram input concentration.
    Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM| | PubMed
  345. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ| | PubMed
  346. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
    Olson JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ| | PubMed
  347. Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer.
    Lang JE, Liu LC, Lu Y, Jenkins T, Hwang SE, Esserman LJ, Ewing CA, Alvarado M, Morita E, Treseler P, Leong SP| | PubMed
  348. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.
    Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ| | PubMed
  349. The UCSC Cancer Genomics Browser.
    Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T| | PubMed
  350. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.
    Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L| | PubMed
  351. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients.
    Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M, Foster RD, Esserman LJ| | PubMed
  352. When informed, all women do not prefer breast conservation.
    Throckmorton AD, Esserman LJ| | PubMed
  353. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
    Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J| | PubMed
  354. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
    Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F| | PubMed
  355. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer.
    Zakhireh J, Gomez R, Esserman L| | PubMed
  356. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
    Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, Sokol S, Alvarado M, Esserman LJ, Morita E, Treseler P, Leong SP| | PubMed
  357. Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center.
    Belkora JK, Loth MK, Chen DF, Chen JY, Volz S, Esserman LJ| | PubMed
  358. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
    Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM| | PubMed
  359. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.
    Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L| | PubMed
  360. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
    Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ| | PubMed
  361. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
    Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP| | PubMed
  362. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
    Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF| | PubMed
  363. Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow-up interviews about barriers and facilitators to the implementation of consultation planning.
    Belkora J, Edlow B, Aviv C, Sepucha K, Esserman L| | PubMed
  364. Optimizing the total skin-sparing mastectomy.
    Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ| | PubMed
  365. A role for biomarkers in the screening and diagnosis of breast cancer in younger women.
    Esserman LJ, Shieh Y, Park JW, Ozanne EM| | PubMed
  366. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R| | PubMed
  367. Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer.
    Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman LJ| | PubMed
  368. Pilot trial of a computerized decision aid for breast cancer prevention.
    Ozanne EM, Annis C, Adduci K, Showstack J, Esserman L| | PubMed
  369. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL| | PubMed
  370. Analysis of molecular inversion probe performance for allele copy number determination.
    Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M| | PubMed
  371. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
    Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW| | PubMed
  372. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES| | PubMed
  373. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.
    Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ| | PubMed
  374. Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
    Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM| | PubMed
  375. Breast cancer growth prevention by statins.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC| | PubMed
  376. Evaluation of a visit preparation intervention implemented in two rural, underserved counties of Northern California.
    Belkora J, Katapodi M, Moore D, Franklin L, Hopper K, Esserman L| | PubMed
  377. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM| | PubMed
  378. Clinical trials are required to prove the chemopreventive worth of statins.
    Kumar AS, Benz CC, Esserman LJ| | PubMed
  379. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
    Kumar AS, Campbell M, Benz CC, Esserman LJ| | PubMed
  380. Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography.
    Esserman L, Sexton R, Yu QQ, Cabello-Inchausti B| | PubMed
  381. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations.
    Ozanne EM, Klemp JR, Esserman LJ| | PubMed
  382. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN, National Comprehensive Cancer Network| | PubMed
  383. Statins: health-promoting agents show promise for breast cancer prevention.
    Kumar AS, Esserman LJ| | PubMed
  384. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.
    Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM| | PubMed
  385. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI| | PubMed
  386. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer.
    Tan YY, Wu CT, Fan YG, Hwang S, Ewing C, Lane K, Esserman L, Lu Y, Treseler P, Morita E, Leong SP| | PubMed
  387. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
    Fan YG, Tan YY, Wu CT, Treseler P, Lu Y, Chan CW, Hwang S, Ewing C, Esserman L, Morita E, Leong SP| | PubMed
  388. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients.
    Tan YY, Fan YG, Lu Y, Hwang S, Ewing C, Esserman L, Morita E, Treseler P, Leong SP| | PubMed
  389. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
    Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM| | PubMed
  390. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
    Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA| | PubMed
  391. Immune dysfunction and micrometastases in women with breast cancer.
    Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ| | PubMed
  392. Integration of imaging in the management of breast cancer.
    Esserman L| | PubMed
  393. Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans.
    Misell LM, Hwang ES, Au A, Esserman L, Hellerstein MK| | PubMed
  394. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease.
    Foster RD, Hansen SL, Esserman LJ, Hwang ES, Ewing C, Lane K, Anthony JP| | PubMed
  395. Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment.
    Park C, Seid P, Morita E, Iwanaga K, Weinberg V, Quivey J, Hwang ES, Esserman LJ, Leong SP| | PubMed
  396. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.
    Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, Esserman L, Shaw L, McLennan J, Strachowski L, Luce J, Ziegler J| | PubMed
  397. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
    Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES| | PubMed
  398. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
    Ozanne EM, Esserman LJ| | PubMed
  399. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.
    Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM| | PubMed
  400. Applying the neoadjuvant paradigm to ductal carcinoma in situ.
    Esserman L, Sepucha K, Ozanne E, Hwang ES| | PubMed
  401. Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.
    Esserman L| | PubMed
  402. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
    Hwang ES, Esserman L| | PubMed
  403. An XML message broker framework for exchange and integration of microarray data.
    Tjandra D, Wong S, Shen W, Pulliam B, Yu E, Esserman L| | PubMed
  404. Racial differences in mammographic breast density.
    del Carmen MG, Hughes KS, Halpern E, Rafferty E, Kopans D, Parisky YR, Sardi A, Esserman L, Rust S, Michaelson J| | PubMed
  405. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
    Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ| | PubMed
  406. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.
    Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM| | PubMed
  407. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
    Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM| | PubMed
  408. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients.
    Wu CT, Morita ET, Treseler PA, Esserman LJ, Hwang ES, Kuerer HM, Santos CL, Leong SP| | PubMed
  409. Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions.
    Parisky YR, Sardi A, Hamm R, Hughes K, Esserman L, Rust S, Callahan K| | PubMed
  410. Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template.
    Sepucha KR, Belkora JK, Aviv C, Mutchnik S, Esserman LJ| | PubMed
  411. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
    Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM| | PubMed
  412. Axillary metastasis from a malignant mullerian mixed tumor.
    Cura MA, Blanco M, Esserman L| | PubMed
  413. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
    Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM| | PubMed
  414. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G| | PubMed
  415. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians.
    Sepucha KR, Belkora JK, Mutchnick S, Esserman LJ| | PubMed
  416. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ, Wollish WS, Lobo M, Esserman LJ| | PubMed
  417. Magnetic resonance imaging for primary breast cancer management: current role and new applications.
    Esserman L, Wolverton D, Hylton N| | PubMed
  418. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma.
    Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H| | PubMed
  419. New approaches to the imaging, diagnosis, and biopsy of breast lesions.
    Esserman LJ| | PubMed
  420. Improving the accuracy of mammography: volume and outcome relationships.
    Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A| | PubMed
  421. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.
    Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB| | PubMed
  422. Does timely assessment affect the anxiety associated with an abnormal mammogram result?
    Haas J, Kaplan C, McMillan A, Esserman LJ| | PubMed
  423. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
    Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N| | PubMed
  424. The impact of alternative practices on the cost and quality of mammographic screening in the United States.
    Burnside E, Belkora J, Esserman L| | PubMed
  425. Ductal growth is impeded in mammary glands of C-neu transgenic mice.
    Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G| | PubMed
  426. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
    Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM| | PubMed
  427. Integration of breast imaging into cancer management.
    Esserman LJ, Wolverton D, Hylton N| | PubMed
  428. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
    Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM| | PubMed
  429. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
    Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ| | PubMed
  430. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer.
    Sepucha KR, Belkora JK, Tripathy D, Esserman LJ| | PubMed
  431. Management of ductal carcinoma in situ.
    Hwang ES, Esserman LJ| | PubMed
  432. Biological therapies for breast carcinoma: concepts for improvement in survival.
    Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM| | PubMed
  433. Prophylactic mastectomy in women with a high risk of breast cancer.
    Kuerer HM, Hwang ES, Esserman LJ| | PubMed
  434. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ| | PubMed
  435. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.
    Esserman L, Hylton N, George T, Weidner N| | PubMed
  436. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
    Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E| | PubMed
  437. A multicenter randomized trial of DIAC for cyclical mastopathy.
    Ballagh SA, Stover TL, Maragos TG, Reynolds MD, Wolfley GD, Esserman LJ, Herbst JR, Kirkegaard LW, Teichman SL| | PubMed
  438. Is routine frozen section assessment feasible in the practice environment of the 1990s?
    Esserman L, Weidner N| | PubMed
  439. Hormone replacement therapy and breast cancer risk.
    Burke CC, Gullatte MM, Vigliani M, Ruggiero RJ, Esserman L, Crawford B| | PubMed
  440. Ultrasound tissue characterization of breast biopsy specimens: expanded study.
    Mortensen CL, Edmonds PD, Gorfu Y, Hill JR, Jensen JF, Schattner P, Shifrin LA, Valdes AD, Jeffrey SS, Esserman LJ| | PubMed
  441. Barriers to care and treatment: the challenge of daily radiation therapy.
    Igoe S, Collins C, Hamolsky D, Esserman LJ| | PubMed
  442. Should we recommend screening mammography for women aged 40 to 49?
    Esserman L, Kerlikowske K| | PubMed
  443. Breast.
    Weidner N, Esserman LJ| | PubMed
  444. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
    Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD| | PubMed
  445. Potentially ineffective care. A new outcome to assess the limits of critical care.
    Esserman L, Belkora J, Lenert L| | PubMed
  446. Cost per anomaly: what does a diaphragmatic hernia cost?
    Metkus AP, Esserman L, Sola A, Harrison MR, Adzick NS| | PubMed
  447. An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site.
    Takahashi S, Esserman L, Levy R| | PubMed
  448. Follicular lymphoma: a model of lymphoid tumor progression in man.
    Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S| | PubMed
  449. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  450. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  451. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
    Campbell MJ, Esserman L, Levy R| | PubMed
  452. Myocardial performance and extracellular ionized calcium in a severely failing human heart.
    Ginsburg R, Esserman LJ, Bristow MR| | PubMed
  453. A novel method for emergency immobilization of the wrist during cross-country skiing.
    Goldman MP, Esserman LJ, Bausback KN, Camargo CA, Nagel DA| | PubMed